TMCnet News
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford Facility-- Bioreactors Now Online and Able to Meet Needs of Current and Future Clients -- -- State-of-the-Art Myford Facility Features Industry-Leading Flexibility, Scalability and Ease-of-Use -- TUSTIN, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced the successful installation and validation of two Mobius® 2,000-liter single-use bioreactors from MilliporeSigma in Avid’s Myford clinical and commercial manufacturing facility. The bioreactors are officially online and able to accommodate the growing demand for larger scale single-use bioreactors from current and future Avid clients. Avid has already secured customer commitments for a portion of the manufacturing capacity associated with the new bioreactors. “We have been working diligently on the installation and validation of these new 2,000-liter bioreactors and are excited to now be in a position to launch the manufacturing activities that this state-of-the-art equipment enables. This enhancement of our capabilities is just the latest step in our ongoing efforts to expand and diversify our customer base,” said Roger Lias, Ph.D., president of Avid Bioservices. “Importantly, based on the modular design of our Myford facility, we have the ability to install one additional 2,000-liter bioreactor, allowing us to further accelerate the growth of the business.” The newly installed 2,000-liter single-use bioreactors offer a range of important manufacturing advantages and efficiencies as compared to other equipment. Traditionally, biopharmaceutical companies used large stainless steel vessels in multi-story buildings, requiring substantial investment and rigorous setup. With single-use disposable equipment, customers get improved batch turnaround times, reduced risk of product cross-contamination, decreased capital costs and have less equipment to clean. Single-use technology helps accelerate customers’ molecules to market, improve productivity, and ensure supply continuity.
The 42,000 square foot Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process. A wide range of innovative features are incorporated into this new facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions. Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing. About Avid Bioservices, Inc. About Peregrine Pharmaceuticals, Inc. Contacts: Kelly Pisarev Lord Avid Bioservices, Inc. (800) 987-8256 Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected] |